Cargando…

Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence

PURPOSE OF REVIEW: We summarize the best evidence for statins in the prevention and treatment of heart failure. RECENT FINDINGS: In patients with cardiovascular risk factors or established atherosclerotic cardiovascular disease (but without heart failure), statins reduce the risk of incident heart f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Matthew M. Y., Sattar, Naveed, McMurray, John J. V., Packard, Chris J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Statin Drugs (M. Tikkanen, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660504/ https://www.ncbi.nlm.nih.gov/pubmed/31350612 http://dx.doi.org/10.1007/s11883-019-0800-z

Ejemplares similares

Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients
por: Strandberg, Timo E.
Publicado: (2019)

An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial
por: Lorgelly, Paula K., et al.
Publicado: (2010)

A Review of the Rationale for Additional Therapeutic Interventions to Attain Lower LDL-C When Statin Therapy Is Not Enough
por: Shanes, Jeffrey G.
Publicado: (2011)

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
por: Packard, Chris J.
Publicado: (2022)

Statin Intolerance: the Clinician’s Perspective
por: Stulc, Tomáš, et al.
Publicado: (2015)

The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia
por: Pang, Jing, et al.
Publicado: (2020)

PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology
por: Altschmiedová, Tereza, et al.
Publicado: (2022)

LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
por: Kayikcioglu, Meral
Publicado: (2021)

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
por: Fruchart, Jean-Charles, et al.
Publicado: (2021)

Lipid Lowering Drugs: Present Status and Future Developments
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents
por: Cohen, Hofit, et al.
Publicado: (2021)

The Role of High-Density Lipoprotein Cholesterol in 2022
por: Sirtori, Cesare R., et al.
Publicado: (2022)

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
por: Martin, Anna, et al.
Publicado: (2022)

Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?
por: Parhofer, Klaus G.
Publicado: (2021)

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

Use of statins after liver transplantation is associated with improved survival: results of a nationwide study
por: Becchetti, Chiara, et al.
Publicado: (2022)

Glycaemic Effects of Non-statin Lipid-Lowering Therapies
por: Collins, Patrick D., et al.
Publicado: (2016)

Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
por: Fruchart, Jean-Charles, et al.
Publicado: (2020)

Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
por: Stefanutti, Claudia
Publicado: (2020)

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
por: Penson, Peter E., et al.
Publicado: (2020)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

RNA Silencing in the Management of Dyslipidemias
por: Henney, Neil C., et al.
Publicado: (2021)

Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
por: Cicero, Arrigo F. G., et al.
Publicado: (2021)

Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
por: Visser, Jolien, et al.
Publicado: (2022)

Understanding the Co-Epidemic of Obesity and COVID-19: Current Evidence, Comparison with Previous Epidemics, Mechanisms, and Preventive and Therapeutic Perspectives
por: Dalamaga, Maria, et al.
Publicado: (2021)

Heart failure induced by itraconazole
por: Okuyan, Hızır, et al.
Publicado: (2013)

Sex Differences in the Excess Risk of Cardiovascular Diseases Associated with Type 2 Diabetes: Potential Explanations and Clinical Implications
por: Peters, Sanne A. E., et al.
Publicado: (2015)

Risk of congenital anomalies in pregnant users of statin drugs
por: Ofori, Benjamin, et al.
Publicado: (2007)

Mitochondria as Therapeutic Targets in Heart Failure
por: Schwemmlein, Julia, et al.
Publicado: (2022)

Treatment of Iron Deficiency in Heart Failure
por: Shamsi, Aamir, et al.
Publicado: (2023)

Mediterranean Diet and Obesity-related Disorders: What is the Evidence?
por: Muscogiuri, Giovanna, et al.
Publicado: (2022)

Change of Heart: the Epitranscriptome of Small Non-coding RNAs in Heart Failure
por: Woudenberg, Tamar, et al.
Publicado: (2022)

Is there a place for angiotensin receptor-neprilysin inhibitors in the treatment of heart failure patients after heart transplantation?
por: Gulin, Dario, et al.
Publicado: (2019)

High-Sensitivity Troponin T and Incident Heart Failure in Older Men: British Regional Heart Study
por: Welsh, Paul, et al.
Publicado: (2019)

Myopathy induced by statin-ezetimibe combination: Evaluation of potential risk factors
por: Brahmachari, Ballari, et al.
Publicado: (2015)

Anti-VEGF drugs in the prevention of blindness
por: Yorston, David
Publicado: (2014)

Inotropes and Inodilators for Acute Heart Failure: Sarcomere Active Drugs in Focus
por: Nagy, László, et al.
Publicado: (2014)

Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction
por: Veenis, Jesse F, et al.
Publicado: (2019)

Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities
por: Fowler, Stephen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_li8b3uqbvlim9j6dddhp82abgr